Development Pipeline

as of February, 2026

Therapeutic Area Development Code
(Generic name)
Development Stage Indication Note
Gastrointestinal
diseases
AJG555 Submission

Chronic constipation in children under 2 years of age
(Additional Dosage and Administration)

Oral
AJM347 Phase Ⅰ Inflammatory bowel disease Oral
EA1080 Phase Ⅰ Inflammatory bowel disease Oral
EA3571 Phase Ⅰ Nonalcoholic steatohepatitis Oral
 Mental disorder  EA8001  Phase Ⅲ

Treatment-resistant schizophrenia with an inadequate response to at least two antipsychotics

 Oral

※スワイプできます

※表は左右にスクロールできます

You are now leaving the EA Pharma website.

Thank you for browsing the EA Pharma website.
You are about to visit an external website.
(A new browsing window will be opened)

Click here to proceed